Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    23-May-2000      
Issue 40 Next Update - 14:00 UTC 08:00 EST    24-May-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya




















Back To Vidyya Current Phase III, Randomized High Dose Chemotherapy Trials With Progenitor Cell Support In Breast Cancer

Treatment And Supportive Care Studies

The table below contains links to information about ongoing phase III, randomized, high-dose, chemotherapy trials that include progenitor-cell support sections in the clinical trial. Patients and provider are invited to follow the links for more information.

Protocol Number (NCI and Institution or Group) Protocol Title Lead Institution
S9623

SWOG

ECOG

CALGB

NCCTG

NCI HIGH-PRIORITY CLINICAL TRIAL--Phase III Randomized Study of Intensive Sequential Doxorubicin, Paclitaxel, and Cyclophosphamide vs Doxorubicin/Cyclophosphamide Followed by STAMP I or STAMP V Combination Chemotherapy with Autologous Stem Cell Rescue in Women with Primary Breast Cancer and 4-9 Involved Axillary Lymph Nodes University of Colorado Cancer Center, Colorado
FHCRC-1316.00

NCI-G99-1552

PSOC-1604

Phase III Randomized Study of High Dose Busulfan, Melphalan, and Thiotepa Versus Cyclophosphamide, Thiotepa, and Carboplatin Followed By Autologous Peripheral Blood Stem Cell Transplantation in Patients with Node Positive Stage II or IIIA Breast Cancer Fred Hutchinson Cancer Research Center, Washington
IBCSG-15-95

EU-96021

Phase III Randomized Study of Adjuvant High-Dose Combination Chemotherapy with Peripheral Blood Stem Cell and G-CSF Support vs Adjuvant Sequential Standard Dose Combination Chemotherapy for Pre- and Postmenopausal Women Younger Than 66 Years with High-Risk, Operable, Stage II/III Breast Cancer Royal Melbourne Hospital, Australia
SCTN-BR9810

EU-98054

Phase III Randomized Study of Conventional versus High Dose Chemotherapy in Women with Node Positive Breast Cancer at Surgery Following Preoperative Primary Chemotherapy C.R.C. Beatson Laboratories Glasgow, Scotland
SCTN-BR9405

EU-95048

Phase III Randomized Study of Doxorubicin Induction Followed by Either Conventional Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) or High Dose Cyclophosphamide and Thiotepa with Peripheral Blood Stem Cell Rescue for Stage II or IIIA Breast Cancer Western General Hospital Edinburgh, Scotland
FRE-FNCLCC-PEGASE03

EU-96032

Phase III Randomized Study of Intensification with Cyclophosphamide/Thiotepa (CHUT) with Autologous PBSC Support vs No Intensification in Locally Recurrent or Metastatic Breast Cancer Responsive to Induction with Epirubicin/Fluorouracil/Cyclophosphamide (FEC 100) Centre Leon Berard
Lyon, France
NCI-G96-1014

MDA-DM-95047

Phase III randomized comparison of high dose chemotherapy plus Filgrastim to Filgrastim for mobilization of peripheral blood stem cells for autologous transplantation for patients with responsive metastatic breast cancer or high risk stage II and III patients University of Texas MD Anderson, Texas
NCI-G97-1145

CCCWFU-95496

Phase III trial of Filgrastim (G-CSF) primed autologous bone marrow versus peripheral blood progenitor cells (PBPC) as hematopoietic support for high dose Cyclophosphamide, Thiotepa, and Carboplatin Therapy (CTCb) in poor prognosis breast cancer Wake Forest University Comp. Cancer Center, North Carolina


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.